Siemens takes control of "lab-on-a-chip" device
This article was originally published in Clinica
In what could mark the company's entry into the near-patient testing market, Siemens Medical Solutions has taken developmental control of a biochip technology, or, so-called "lab-on-a-chip" device, called Quicklab. The company, more traditionally associated with providing for the medical imaging industry, said it aimed to take the product to market readiness.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.